Categories
Change Password!
Reset Password!
Once-daily vildagliptin XR 100 mg markedly improves HbA1c, and fasting and postprandial glucose levels in people with type 2 diabetes uncontrolled on metformin.
A new real-world clinical study involving over 1,600 patients has confirmed that once-daily vildagliptin sustained-release (XR) 100 mg markedly improves blood sugar control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled on metformin monotherapy. Vildagliptin XR is a newer formulation designed to simplify diabetes care by allowing once-daily dosing while maintaining effective glycemic control. The study, which was observational, prospective, and multicenter in design, aimed to determine the drug’s effectiveness, tolerability, and safety in routine clinical settings.
Conducted at 118 centers, the study enrolled 1,691 adults (mean age approximately 53 years) with T2DM whose glycated hemoglobin (HbA1c) levels were above 7.0% despite treatment with metformin XR. The average HbA1c at baseline was 8.44%, indicating poor glycemic control. Patients continued their metformin XR therapy and were prescribed vildagliptin XR 100 mg once daily. The key endpoint was the alteration in HbA1c after 3 months. Secondary endpoints included alteration in fasting plasma glucose, postprandial plasma glucose, the percentage of people achieving HbA1c < 7.0%, and assessments of the drug’s safety and tolerability.
After 3 months of treatment:
The study also portrayed a favorable safety profile for vildagliptin XR. Only 3 adverse events were reported during the study period, all of which were mild and resolved without complications. No serious adverse effects were observed. Thus, vildagliptin XR 100 mg once daily depicted remarkable improvements in key glycemic parameters and was well-tolerated by the patients. These findings provide real-world evidence supporting its role as a valuable add-on therapy in T2DM care.
Drugs-Real World Outcomes
Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study]
Rakesh Sahay et al.
Comments (0)